Symbol | Exchange | Currency |
|---|
By Sarah White PARIS (Reuters) - French drugmaker Sanofi (NASDAQ:SNY) has agreed to buy British immunotherapy firm Kymab for up to $1.45 billion, the latest in a string of deals...
By Pamela Barbaglia and Joshua Franklin LONDON/NEW YORK (Reuters) - Mergers and acquisitions came back with a bang in the third quarter as executives rushed to revisit deals left...
By Peter Nurse Investing.com - European stock markets are set to open higher Friday, buoyed by the U.S. Federal Reserve’s new monetary policy framework which will likely see...
Sanofi (NASDAQ:SNY) SNY announced an agreement to acquire Kymab, a small biotech for an upfront payment of approximately $1.1 billion and potential milestone payments of up to $350...
Shares of biotechnology company Momenta Pharmaceuticals, Inc. MNTA were up 69.17% after it announced that it will be acquired by pharma giant Johnson & Johnson (NYSE:JNJ) JNJ...
Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immune-mediated diseases. The company developing rilzabrutinib, an inhibitor that is in Phase III clinical trials for the treatment of pemphigus, a chronic skin disease, as well as and pemphigus foliaceus; in a Phase 1/2 trial for the treatment of immune thrombocytopenia; and a Phase 2 trial for the treatment of IgG4-related disease. It is also developing PRN2246/SAR442168, an inhibitor, which is in Phase Ii clinical trial for treating multiple sclerosis (MS) and other central nervous systems (CNS) diseases; and PRN473, a drug candidate that is in Phase I clinical trial for the treatment of immune-mediated diseases. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is based in South San Francisco, California. As of September 25, 2020, Principia Biopharma Inc. operates as a subsidiary of Sanofi.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | |||||
| Technical Indicators | |||||
| Summary |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 193.88 | 195.28 | 189.44 | +4.69 | +2.48% | 122.39M | NASDAQ | |||
| 160.77 | 161.04 | 159.35 | +3.12 | +1.98% | 48.98M | NASDAQ | |||
| 61.87 | 61.95 | 61.59 | +0.45 | +0.73% | 6.96M | NYSE | |||
| 205.35 | 205.72 | 202.54 | +4.67 | +2.33% | 18.20M | NASDAQ | |||
| 101.39 | 102.43 | 100.65 | +0.36 | +0.36% | 28.11M | NASDAQ | |||
| 280.51 | 281.14 | 278.41 | +5.28 | +1.92% | 24.00M | NASDAQ | |||
| 40.25 | 40.26 | 39.99 | +0.26 | +0.65% | 11.98M | NYSE | |||
| 96.09 | 96.91 | 94.87 | +1.53 | +1.62% | 54.70M | NASDAQ | |||
| 100.25 | 100.42 | 98.58 | +3.01 | +3.10% | 48.31M | NASDAQ | |||
| 162.13 | 162.68 | 160.15 | +3.15 | +1.98% | 1.71M | NASDAQ | |||
| 269.84 | 270.77 | 265.97 | +5.74 | +2.17% | 38.29M | NASDAQ | |||
| 8.22 | 8.25 | 8.05 | +0.22 | +2.81% | 14.65M | NYSE | |||
| 101.90 | 102.79 | 101.04 | +0.54 | +0.53% | 25.46M | NASDAQ | |||
| 46.70 | 46.73 | 44.75 | +2.39 | +5.39% | 13.80M | NYSE | |||
| 51.17 | 51.27 | 50.64 | +0.78 | +1.55% | 15.40M | NASDAQ |